Northwest Biotherapeutics reported $82.97M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Agenus USD 231.82M 17.42M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Celldex Therapeutics USD 61.32M 9.85M Jun/2026
Eisai JPY 393.64B 53.39B Jun/2026
Merck USD 27.73B 786M Jun/2026
Northwest Biotherapeutics USD 82.97M 4.93M Mar/2026
Pfizer USD 32.65B 1.7B Jun/2026
Plus Therapeutics USD 8.57M 612K Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026